

Table S1 The search strategies in PubMed

("Myasthenia Gravis"[Mesh] OR (((("myasthenia gravis"[MeSH Terms] OR ("myasthenia"[All Fields] AND "gravis"[All Fields]) OR "myasthenia gravis"[All Fields]) AND Ocular[Title/Abstract]) OR Ocular Myasthenia Gravis[Title/Abstract]) OR (("myasthenia gravis"[MeSH Terms] OR ("myasthenia"[All Fields] AND "gravis"[All Fields]) OR "myasthenia gravis"[All Fields]) AND Generalized[Title/Abstract])) OR Generalized Myasthenia Gravis[Title/Abstract])) AND (((((((((((MicroRNA[Title/Abstract] OR miRNAs[Title/Abstract] OR Micro RNA[Title/Abstract] OR ("rna"[MeSH Terms] OR "rna"[All Fields]) AND Micro[Title/Abstract])) OR miRNA[Title/Abstract] OR Primary MicroRNA[Title/Abstract] OR ("micronas"[MeSH Terms] OR "micronas"[All Fields] OR "microna"[All Fields]) AND Primary[Title/Abstract])) OR Primary miRNA[Title/Abstract] OR ("micronas"[MeSH Terms] OR "micronas"[All Fields] OR "mirna"[All Fields]) AND Primary[Title/Abstract])) OR pri-miRNA[Title/Abstract] OR pri miRNA[Title/Abstract] OR ("rna"[MeSH Terms] OR "rna"[All Fields]) AND Small Temporal[Title/Abstract])) OR (Temporal[All Fields] AND ("rna"[MeSH Terms] OR "rna"[All Fields]) AND Small[Title/Abstract])) OR stRNA[Title/Abstract] OR Small Temporal RNA[Title/Abstract] OR pre-miRNA[Title/Abstract] OR pre miRNA[Title/Abstract]) AND "MicroRNAs"[Mesh])

((("Myasthenia Gravis"[Mesh] OR (((Myasthenia Gravis, Ocular[Title/Abstract]) OR Ocular Myasthenia Gravis[Title/Abstract]) OR Myasthenia Gravis, Generalized[Title/Abstract]) OR Generalized Myasthenia Gravis[Title/Abstract])) AND (("Polymorphism, Genetic"[Mesh] OR (((Polymorphisms, Genetic[Title/Abstract]) OR Genetic Polymorphism[Title/Abstract]) OR Polymorphism (Genetics)[Title/Abstract]) OR Genetic Polymorphisms[Title/Abstract])))

((("Myasthenia Gravis"[Mesh] OR (((Myasthenia Gravis, Ocular[Title/Abstract]) OR Ocular Myasthenia Gravis[Title/Abstract]) OR Myasthenia Gravis, Generalized[Title/Abstract]) OR Generalized Myasthenia Gravis[Title/Abstract])) AND (("Polymorphism, Single Nucleotide"[Mesh] OR (((Nucleotide Polymorphism, Single[Title/Abstract]) OR Nucleotide Polymorphisms, Single[Title/Abstract]) OR Polymorphisms, Single Nucleotide[Title/Abstract]) OR Single Nucleotide Polymorphisms[Title/Abstract]) OR SNPs[Title/Abstract]) OR Single Nucleotide Polymorphism[Title/Abstract])))

((("Myasthenia Gravis"[Mesh] OR (((Myasthenia Gravis, Ocular[Title/Abstract]) OR Ocular Myasthenia Gravis[Title/Abstract]) OR Myasthenia Gravis, Generalized[Title/Abstract]) OR Generalized Myasthenia Gravis[Title/Abstract])) AND (("Genome-Wide Association Study"[Mesh] OR (((((((((((Association Studies, Genome-Wide[Title/Abstract]) OR Association Study, Genome-Wide[Title/Abstract]) OR Genome-Wide Association Studies[Title/Abstract]) OR Studies, Genome-Wide Association[Title/Abstract]) OR Study, Genome-Wide Association[Title/Abstract]) OR Genome Wide Association Scan[Title/Abstract]) OR Genome Wide Association Studies[Title/Abstract]) OR GWA Study[Title/Abstract]) OR GWA Studies[Title/Abstract]) OR Studies, GWA[Title/Abstract]) OR Study, GWA[Title/Abstract]) OR Whole Genome Association Analysis[Title/Abstract]) OR Whole Genome Association Study[Title/Abstract]) OR Genome Wide Association Analysis[Title/Abstract]) OR Genome Wide Association Study[Title/Abstract])))

Table S2 Reported SNPs and genes related to MG risk

PMID	Authors	Gene	Genotype	Ethnic group or descent	Cases	Healthy controls	Odds ratio (95% CI) or other results
28364296	Yu Hong (39)	AIRE	rs3761389	Chinese	114 Adult MG (18–40 years)	487	P=0.01, CI: 1.38 (1.07–1.78)
28364296	Yu Hong (39)	CTLA-4	rs231775	Chinese	114 Juvenile MG (1–18 years)	487	P=0.02, CI:0.64 (0.44–0.93)
28364296	Yu Hong (39)	CTLA-4	rs733618	Chinese	114 Juvenile MG (1–18 years)	487	P=0.005, CI:1.60 (1.15–2.22)
28364296	Yu Hong (39)	CHRNA1	rs16862847	Chinese	114 Juvenile MG (1–18 years)	487	P=0.03, CI:2.04 (1.06–3.90)
28364296	Yu Hong (39)	CHRNA1	rs2229957	Chinese	114 Juvenile MG (1–18 years)	487	P=0.0005, CI:2.64 (1.50–4.63)
28364296	Yu Hong (39)	CHRNA1	rs16862847	Chinese	207 Adult MG (18–40 years)	487	P=0.006, CI:2.03 (1.21–3.41)
10606977	Xu BY (40)	ADRB2	Arg/Arg	Swedish	145MG (Ocular =10; Generalized =135)	96 HC	P=0.0022 OR=3.60 (1.52–8.54)
10606977	Xu BY (40)	ADRB2	Gly/Gly	Swedish	145MG (Ocular =10; Generalized =135)	96 HC	P=0.0079 OR=0.45 (0.26–0.81)
10606977	Xu BY (40)	ADRB2	Carriage of Gly	Swedish	145MG (Ocular =10; Generalized =135)	96 HC	P=0.0022 OR=0.27 (0.12–0.66)
27338803	Wang L (41)	ADRB2	-	-	27 MG	-	P=0.041
1352699	Degli-Esposti MA (42)	BAT1	8.1 ancestral haplotype (HLA A1, Cw7, B8, BfS, C4Aq0, C4B1, DR3, DQw2)	Caucasoid	16 MG	16 adult Caucasoid subjects from Busseton	RR =5.5
19513280	Kim HS (43)	CCR2	rs1799864	Korean	109MG	115	P<0.05
11857062	Wang XB (44)	CTLA4	+49 A/G	Sweden	15 MG(+) Thymoma 30 MG(+) thymic hyperplasia 11 MG(+) normal thymus	122	Thymoma vs. normal and hyperplastic thymic: 8.44 (1.77–40.4)
16178018	Chuang WY (45)	CTLA4	+49A/G	German	79 MG(+) thymoma	46 MG(-) thymoma	129 non-thymoma EOMG
18088253	Wang XB (46)	CTLA4	-1772T/C -1661A/G	Sweden	165 MG	148	1.87 (1.01–3.49)
24373506	Chuang WY (47)	CTLA4	+49A/G	Caucasian	116 LOMG patients	172	P=0.0029,2.7(1.7–4.0)
19345707	Fernández-Mestre M (48)	CTLA4	49 A/G	Venezuelans	46 MG	98 HC	P>0.05
18595775	Gu (49)	CTLA-4	RQ sCTLA-4/(RQ sCTLA-4 + RQ mCTLA-4)	Swedish Caucasian	52 MG patients	31 healthy individuals	P<0.05
12225905	Wang XB (50)	CTLA-4	(AT)n polymorphism in the 3'-untranslated region	Swedish Caucasian	96 AChR(+) MG patients	100 ethnically matched healthy individuals	p<0.0001; r=0.396,
25643325	Renton AE (51)	CTLA4	rs231770	white individuals from North America; Italian cases	1032acetylcholine receptor antibody-positive myasthenia gravis	1998 healthy individuals	1.37; 95% CI, 1.25–1.49
25643325	Renton (51)	TNFRSF11A	rs4263037	white individuals from North America	the late-onset cases in 1032 acetylcholine receptor antibody-positive myasthenia gravis	1998 healthy individuals	1.41; 95% CI, 1.29–1.53
25003519	Sun L (52)	CTLA4	rs1863800 rs733618 rs231775	Chinese	168 patients with MG	233 healthy controls	ROCAUC value:0.570;CI:0.513-0.626 ROCAUC value:0.580;CI:0.523-0.638 ROCAUC value:0.568;CI:0.512-0.625
11426323	Ligers A (53)	CTLA4	-318C/C	Sweden	29 MG	26 HC	P<0.05
11574100	Franciotta D (54)	C4A	C4A/Q0	Italian	81 MG	100 HC	P<0.05, RR=2.2 vs. controls(MG female)
11574100	Franciotta D (54)	HLA	DRB1 03	Italian	81 MG	100 HC	P<0.005, RR=7.8 vs. controls(MG female)
11574100	Franciotta D (54)	TNFB	TNFB 1	Italian	81 MG	100 HC	P<0.05, RR=7.0 vs. controls(MG female)
20942939	Ramanujam R (55)	CIITA	rs3087456	Swedish	446 MG patients	1866 HC	P=0.092; 0.86 (0.73–1.02)
7910962	Garchon HJ (56)	CHRNA	HB*14 allele	Caucasian	81 generalized MG	100 MG	P<0.0002
17687331	Giraud M (57)	CHRNA1	rs16862847	French United Kingdom	330 EOMG	260	EOMG: 2.19(1.41–3.39)
14735155	Giraud M (58)	CHRNA1	268 allele	French	350 MG	168	thymoma(-)MG: 1.78 (1.037– +∞) anti-titin (-)MG:2.07 (1.16– +∞)
17869649	Viken MK (59)	CTSL2	rs4361859	German	83 MG patients 31 EOMG	244 HC	EOMG OR = 1.82, 95% CI: 1.07–3.12, P= 0.03
19675582	JM Heckmann (60)	DAF	rs28371586	African	139 EOP	167	8.6 (2.8–26.1)
22744667	Landouré G (61)	ENOX1	D13S219 - D13S326	-	Seven family members (4 MG, 2 unaffected, and 1 with uncertain diagnosis)	764	P < 0.001
14597109	van der Pol WL (62)	FCGR2A	FcγRIIIa-R/R131	Dutch	107 MG patients	239 HC	P<0.01;2.4, 95% CI1.4–3.9
9521619	Raknes G (63)	FCGR2A	FcγRIIIa-H/H	Norwegian Caucasians	30 MG	49 HC	P=0.02
23228687	Zhang JM (64)	FOXP3	IVS9+459 rs2280883	Chinese	118 MG	124	MG(+): 0.44 (0.25–0.79)
19693092	Chuang WY (65)	PTPN22	+1858C/T	German	79 MG(+) thymoma 46 MG(-) thymoma 129 non-thymoma EOMG	172	MG(+) thymoma: 2.66(1.38–5.12) EOMG: 2.81(1.58–5.00)
19406179	Greve B (66)	PTPN22	+1859C/T	German Hungary	50 anti-titin (+) non-thymoma MG	379	anti-titin (+) non-thymoma MG: 2.10 (1.23–3.58)
18533277	Lefvert (67)	PTPN22	W620 variant	Swedish	409MG	1557	1.52 (1.21–1.90)
25119822	Gizem A.Kaya (68)	PTPN22	rs2476601	Turkey	231AChR-MG	293	2.5 (1.2–5.1)
16437561	Vandiedonck C (69)	PTPN22	rs2476601	French	470293 nonthymoma patients without anti-titin 293 nonthymoma patients without anti-titin 293 nonthymoma patients without anti-titin 293MG	296	thymoma(-)anti-titin(-):1.97 (1.32–2.97)
22197427	Provenzano (70)	PTPN22	rs2488457	Caucasian	356MG	439 healthy individuals	2.10 (1.13–3.89)
26318187	Xiong X (71)	PTPN22 R620W	-	Hungary, France, Italy, Turkey, Sweden, Germany (Caucasian)	2802 cases	3730 controls	Overall: (OR=1.57; 95% CI, 1.34–1.82; I ² =31%) EOMG (OR=2.38; 95% CI, 1.52–3.71; I ² =0%) Thymoma: (OR=1.59; 95% CI, 1.28–1.98; I ² =0%)
23076337	Zheng J (72)	PTPN22	C1858T		1286 MG	2404 HC	OR=1.53; 95% CI:1.31–1.80, P=1.09 × 10 ⁻⁷
23055271	Gregersen PK (73)	PTPN22	rs2476601	North European	649 EOMG	2596 HC	OR = 1.71, P=8.2 × 10 ⁻¹⁶ ; 95% CI:1.44–2.02
23055271	Gregersen PK (73)	TNIP1	rs2233287 rs4958881	North European	649 EOMG	2596 HC	EOMG rs2233287: 1.73 (1.44–2.08) rs4958881: 1.71 (1.44–2.02)
23055271	Gregersen PK (73)	HLA class I region	rs7750641	North European	649 EOMG	2596 HC	P= 1.2 × 10 ⁻⁹⁶ , OR = 6.25 (95% CI: 4.89–6.85)
17509455	Yilmaz V (74)	IFNG	+874T	Mixed	115 patients AChR (+)=92 ATA (+)=32	204 HC	MG: P=0.012, OR =0.5, 95% CI: 0.29–0.86 AChR (+): P=0.01, OR =0.47, 95% CI: 0.27–0.84 ATA (+): P=0.014, OR = 0.36, 95% CI: 0.16–0.79
17509455	Yilmaz V (74)	IL10	-2763A	Mixed	115 patients AChR (+)=92	204 HC	MG: P=0.049, OR =1.69, 95% CI:1–2.85 AChR (+): P=0.036, OR =1.83, 95% CI: 1.04–3.25
25118158	Lili Yang (75)	IGF1R	rs28457673	Chinese	18MG	93	Bioinformatics
22119518	Pál Z (76)	I75V(IL-4R)	rs1805010	Caucasian	214AChR(+)/MG	299	1.77 (1.1–2.84)
11777547	Sciaccia FL (77)	IL1A	-889C/C	Italian	421MG	995	associated with EOMG (P=0.0044) in the whole MG group
9521608	Huang D (78)	IL1B	IL-1β TaqI RFLP(A2/A2)	Swedish caucasian	107 MG patients Thymoma=16.8%; Hyperplasia= 38.3%; Normal =13.1%; UnTx= 31.8%	82 ethnically matched healthy individuals	The frequency of the genotype A2/A2 was significantly increased (P=0.010, Pc=0.030)
10580802	Huang D (79)	IL6	-174A/D	Caucasian	141MG	127	OR=17, p<0.0001
10376939	Huang DR (80)	IL10	134 G/G	Caucasian	149 MG	109	24 thymoma (+) 3.60 (1.80–7.21)
10376939	Huang DR (80)	IL10	IL10.G, allele 134	Swedish Caucasian	149 patients, 97 patients were thymectomized and 24 had thymoma, 51 hyperplasia and 22 normal thymic histology	109 ethnically matched healthy individuals	P=0.0004, pc=0.0192, OR=3.60, 95% CI:1.80–7.21
23049601	Zagoriti Z (81)	IL-10	-	Greeks	101 MG	101 HC	P= 0.068
19299022	Alseth EH (82)	IL-10	ACC/ACC ACC/ATA	Norwegian Caucasians	64 MG patients	87 HC	P=0.05 P=0.03
26337284	Yue YX (83)	IL-17	rs2275913 rs3748067	Han Chinese population	480 MG patients	487 controls	P=0.428; CI, 10.76(0.898–1.289)
20728947	Pal Z (84)	LGALS1 IL2RB	rs4820293 rs4820294 rs743777 rs228941	Hungary	146 MG	291	9.2 (95% CI N.S) P=0.021
22683700	Pál Z (85)	LGALS9	rs2737713	Caucasian	149MG, 214RA and 134 repetitive cohorts	365	anti-AChR (+) MG with RA 3.87 (1.7–8.72)
23932992	Kellermayer B (86)	HNMT	A939G	Caucasian	213 MG (Anti-AChR+= 140; Anti-Titin+=41)	342 HC	(AChR+) P=0.05; 0.67 (0.44–0.95) (Anti-Titin+) P=0.004; 0.54 (0.35–0.84)
22521184	Najibba Fekih-Mrissa (87)	HLA-DRB1 HLA-DQB1	DRB1*04, DRB1*03, DRB1*04, DQB1*02, DQB1*03	Tunisian patients	48 MG patients(37.5% have thymoma)	100 healthy controls	HLA-DRB1*03 (pc <10 ⁻⁵), DRB1*04 (pc = 0.005), DQB1*02 (pc = 0.002) and, DQB1*03 (pc =0.007)
22503410	Zhu WH (88)	HLA-DQA1 HLA-DQB1	DQA1*03:02 DQB1*03:03:02	Southern Han Chinese	205 MG patients	100 HC	childhood-onset ocular MG P<0.0001, OR=17.8
21917268	Yang H (89)	HLA-DQA1 HLA-DQB1	DQA1*01:03 DQB1*06:01	Northern Han Chinese	84 MG patients	293 HC	P=0.000, OR:0.24, 95% CI: 0.13–0.49 P=0.001, OR:0.40, 95% CI: 0.22–0.50
23091703	Testi M (90)	HLA-DQB1	DQB1*05:02	Italian patients	28 (absence of thymoma, the presence of AChR and LOMG)	100 healthy controls	pc = 0.0228
19490212	Hajeer AH (91)	HLA-A	HLA-B*08	Saudi	109 MG HLA-B*08=65	383 HC	OR:2.51;95% CI: 1.64–3.83; P=0.00001
19561379	Yousefpour GA (92)	HLA-DQA1 HLA-DQB1	DQA1*01:01/2 DQB1*05:02	sporadic patients	104MG	816 healthy controls	pc =1.69 pc =2.41
16720217	Saruhan-Direskeneli G (93)	HLA-DQA1 HLA-DQB1	DQA1*01:03 DQB1*05:02	Caucasian	132 MG (AChR antibody(+)=107, AChR antibody(-)=25)	250 healthy unrelated individuals (143 women and 107 men)	DQA1*01:03 (OR: 0.5) DQB1*05:02 (OR: 1.9)
27181991	Saruhan-Direskeneli G (93)	HLA class I region	rs113519545	Turkic	211 EOMG	541HC	P=2.24 × 10 ⁻¹⁰ , CI.5.71(3.77–8.66)
27181991	Saruhan-Direskeneli G (93)	HLA class II region	rs111256513	Turkic	109 LOMG	541HC	P=2.48 × 10 ⁻⁶ , CI.2.22(1.59–3.09)
27181991	Saruhan-Direskeneli G (93)	HLA-DQB1	rs68081734	Turkic	78 MuSK-MG	541HC	P=2.25 × 10 ⁻¹⁴ , CI.5.86(3.72–9.22)
8964894	Hjelmström P (94)	HLA-DQB1	DQB1*02:01	Caucasian	79 MG	155 HC	P<0.05, OR=3.73
19793653	Pal Z (95)	ORα	rs2234693 rs9340799	Caucasian women	113 female myasthenia patients	184 female HC	P>0.05
18037500	Sakthivel P (96)	PDCD1	rs7565639	Sweden	269 MG	275	Significant increase in GG genotype among MG patients (age >40) compared to controls (p=0.0312).
24719132	Na SJ (97)	SLAMF1	rs3753381	Korean	55 AChR antibody positive MG	150HC	P=9.6391 × 10 ⁻⁶
22617007	Kokunai Y (98)	SCN4A	G1292D	Swedish Caucasian	1 acquired autoimmune myasthenia gravis	547 HC	P<0.05
26632886	Nel M (99)	TGFB1	-387C>T	African	OP-MG	1000	
24959269	Zheng K (100)	TIM1	-1637A/G	Chinese	58 MG(+) thymoma	62	Thymoma (MG+) vs. Thymoma (MG+), P=0.031
4063586	Zheng, K. (101)	TIM1	-1637A/G	Han population of North China	58 cases of thymoma with MG, including 28 males and 30 females (mean age, 47.3 years)	62 cases of thymoma without MG, including 38 males and 24 females (mean age, 52.7 years)	The allele frequencies at the -1637A/G polymorphic site were significantly different between thymoma patients with and without MG (P=0.024)
25663933	Xu G (102)	TIM3	GT+TT genotype and T allele on the -574 locus	Han population of North China	116 patients with thymoma and MG	124 patients with thymoma, but without MG	GT+TT: 0.329 (0.171–0.634) T: 0.375 (0.202–0.697)
16075747	Guan YZ (103)	TNF	-308A/A	Chinese	20 MG	20	Significant increase in LOMG patients (age >40) compared to controls (P<0.05)
10376950	Huang DR (104)	TNF	TNF-α -308 allele 2	Swedish caucasian	19 MG patients, Serum AChR-Ab(-)=13.8% Serum AChR-Ab(+)=86.2% Thymoma=17.2% Hyperplasia=39.7% Normal=12.9% UnTx=30.2%	100 ethnically matched healthy individuals	-
28514294	Yang, Hong-Wei (105)	TNFRAP3	rs7749323	47	47 LOMG	235	OR=3.27, 95% CI, 1.01–10.6, P=0.04
9949945	Zelano G (106)	TNFB	TNFB*1	Italy	63 MG patients (Hyperplasia =26; thymoma =17; involuted thymus =6; Not thymectomized =14) Forty-nine patients had been thymectomized: 26 had a thymic hyperplasia, 17 a thymoma and six a normal/involuted thymus.	93 healthy individuals	MG patients with thymic hyperplasia we found a positive association with the TNFB*1 allele [Relative risk (RR): 2.6; P<0.001] and phenotype (RR: 1.8; P<0.005) and a negative association with the TNFB*2/2 genotype (RR: 0.2; P<0.001) MG patients with thymoma we found a positive association with the TNFB*2/2 genotype (RR: 5.6; P<0.01) and a negative association with the TNFB*1 allele (RR: 0.3;P<0.05) and *1/2 genotype (RR: 0.2; P<0.01).
9688335	Hjelmström P (107)	TNFB	TNFA2 TNFA11 TNFB*1 TNFB*2/TNFB*2	Swedish Caucasian	79 MG (51 females and 28 males)	155 unrelated healthy individuals	TNFA2 was positively associated in all MG patients OR= 2.92, 95% CI: 1.57–5.43, Pc<0.01 TNFA11 was found to be decreased in patients with an early onset of disease compared to patients with a later onset OR=0.27, 95% CI: 0.09–0.75, P<0.05, Pc=ns TNFB*1 was observed in patients with an early onset of disease compared to patients with a later onset OR =3.27, 95% CI: 1.19–9.02, Pc<0.05. The frequency of the TNFB*2/TNFB*2 genotype was decreased in patients with an early disease onset OR=0.31, 95% CI: 0.11–0.84, Pc<0.05
23253802	Han JL (108)	VDR	s757343	Chinese	302 MG	283	1.70 (1.07–3.41)

EOMG, early onset MG; OP-MG, ophthalmoplegic complication of MG; EOM, extraocular muscle; LOMG, late-onset; RA, rheumatoid arthritis; p_c denotes Bonferroni corrected probability values; CI, confidence interval.

Table S3 Reported differentially expressed microRNAs in PBMC or serum in between MG cases and healthy controls

PMID	Authors	MG subtype	miRNAs	PBMC or serum	Ethnic group or descent	Fold changes	P value
22835429	Lin Jiang (109)	MG	let-7a	PBMC	Chinese	-41.40	P<0.0001
22835429	Lin Jiang (109)		let-7b	PBMC	Chinese	-28.90	P<0.0001
22835429	Lin Jiang (109)		let-7c	PBMC	Chinese	-52.20	P<0.0001
22835429	Lin Jiang (109)		let-7d	PBMC	Chinese	-33.50	P<0.0001
24962817	Zhangq J (110)	AChR-MG	miR-146a	PBMC	Chinese	4.00	P<0.0100
24036458	Lu J (111)	AChR-MG	miR-146a	B cell	Chinese	3.5	P<0.0100
24043548	Wang J (112)	EAMG	miR-145	PBMC	Chinese	-0.28	0.0130
24387321	Wang (113)	EAMG	miR-155	PBMC	Chinese	8.00	P<0.0010
24637658	Gisela Nogales-Gadea (114)	EOMG	miR-15b	Serum	Turkey	-37.13	P<0.0230
24637658	Gisela Nogales-Gadea (114)	LOMG	miR-122	Serum	Turkey	-311.05	P<0.0010
24637658	Gisela Nogales-Gadea (114)	LOMG	miR-140-3p	Serum	Turkey	-60.60	P<0.0040
24637658	Gisela Nogales-Gadea (114)	LOMG	miR-185	Serum	Turkey	-32.45	0.0020
24637658	Gisela Nogales-Gadea (114)	EOMG	miR-192	Serum	Turkey	-57.62	0.0200
24637658	Gisela Nogales-Gadea (114)	EOMG	miR-20b	Serum	Turkey	-4.48	0.0330
24637658	Gisela Nogales-Gadea (114)	LOMG	miR-885-5p	Serum	Turkey	-148.66	0.0140
23196978	Zhuoan Cheng (115)	MG	miR-320a	Serum	Chinese	-7.1428	0.0433
25356381	Tanel punga (116)	AChR-MG	miR-150-5p	Serum	Swedish	13.2	0.002
			miR-21-5p			3.3	0.011
			miR-27a-3p			-5.8	0.044
3992033	Wang (117)	MG	MiR-155	PBMCs	Chinese	5.8	P<0.05
26845056	Nie Chunjie (118)	MG	miR-20b	Serum	Chinese	0.6	P<0.05
25962782	Yong Zhang (119)	Ocular generalized	miR-181c	PBMCs	Chinese	0.25 0.45	P<0.01 P<0.01
26943954	Tanel Punga (120)	MuSK+ MG	miR-151a-3p	Serum	Roman	2.63	0.000887
			let-7f-5p			3.76	0.01040
			miR-423-5p			4.30	0.0118
			let-7d-3p			3.68	0.0178
			let-7a-5p			2.03	0.0327
			miR-409-3p			4.46	0.0351
26095457	Punga AR (121)	MG	miR-150-5p	Serum	Swedish	2.7	P<0.0001
			miR-21-5p			1.94	P<0.0001

Fold changes: miRNA expressions of MG patients vs. normal controls; EAMG, experimental autoimmune; LOMG, late onset MG; PBMC, peripheral blood mononuclear cell.

References

39. Hong Y, Skeie GO, Zisimopoulou P, et al. Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms. *J Neurol* 2017;264:955-62.
40. Xu BY, Huang D, Pirskanen R, et al. beta2-adrenergic receptor gene polymorphisms in myasthenia gravis (MG). *Clin Exp Immunol* 2000;119:156-60.
41. Wang L, Zhang Y, He M. beta2-Adrenergic receptor gene polymorphisms in the relapse of myasthenia gravis with thymus abnormality. *Int J Neurosci* 2017;127:291-8.
42. Degli-Esposti MA, Leelayuwat C, Dawkins RL. Ancestral haplotypes carry haplotypic and haplospecific polymorphisms of BAT1: possible relevance to autoimmune disease. *Eur J Immunogenet* 1992;19:121-7.
43. Kim HS, Kim DS, Lee EY, et al. CCR2-64I and CCR5Delta32 Polymorphisms in Korean Patients with Myasthenia Gravis. *J Clin Neurol* 2007;3:133-8.
44. Wang XB, Kakoulidou M, Qiu Q, et al. CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. *Genes Immun* 2002;3:46-9.
45. Chuang WY, Strobel P, Gold R, et al. A CTLA4^{high} genotype is associated with myasthenia gravis in thymoma patients. *Ann Neurol* 2005;58:644-8.
46. Wang XB, Pirskanen R, Giscombe R, et al. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. *J Intern Med* 2008;263:61-9.
47. Chuang WY, Strobel P, Bohlender-Willke AL, et al. Late-onset myasthenia gravis - CTLA4^(low) genotype association and low-for-age thymic output of naive T cells. *J Autoimmun* 2014;52:122-9.
48. Fernandez-Mestre M, Sanchez K, Balbas O, et al. Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. *Hum Immunol* 2009;70:532-5.
49. Gu M, Kakoulidou M, Giscombe R, et al. Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis. *Clin Immunol* 2008;128:374-81.
50. Wang XB, Kakoulidou M, Giscombe R, et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. *J Neuroimmunol* 2002;130:224-32.
51. Renton AE, Pliner HA, Provenzano C, et al. A genome-wide association study of myasthenia gravis. *JAMA Neurol* 2015;72:396-404.
52. Sun L, Meng Y, Xie Y, et al. CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population. *PLoS One* 2014;9:e101986.
53. Ligiers A, Teleshova N, Masterman T, et al. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. *Genes Immun* 2001;2:145-52.
54. Franciotta D, Cuccia M, Dondi E, et al. Polymorphic markers in MHC class II/III region: a study on Italian patients with myasthenia gravis. *J Neurol Sci* 2001;190:11-6.
55. Ramanujam R, Zhao Y, Pirskanen R, et al. Lack of association of the CIITA -168A-->G promoter SNP with myasthenia gravis and its role in autoimmunity. *BMC Med Genet* 2010;11:147.
56. Garchon HJ, Djabiri F, Viard JP, et al. Involvement of human muscle acetylcholine receptor alpha-subunit gene (CHRNA) in susceptibility to myasthenia gravis. *Proc Natl Acad Sci U S A* 1994;91:4668-72.
57. Giraud M, Taubert R, Vandiedonck C, et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. *Nature* 2007;448:934-7.
58. Giraud M, Eymard B, Tranchant C, et al. Association of the gene encoding the delta-subunit of the muscle acetylcholine receptor (CHRND) with acquired autoimmune myasthenia gravis. *Genes and Immunity* 2004;5:80-3.
59. Viken MK, Sollid HD, Joner G, et al. Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. *Hum Immunol* 2007;68:748-55.
60. Heckmann JM, Uwimpuhwe H, Ballo R, et al. A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. *Genes Immun* 2010;11:1-10.
61. Landouze G, Knight MA, Stanescu H, et al. A candidate gene for autoimmune myasthenia gravis. *Neurology* 2012;79:342-7.
62. van der Pol WL, Jansen MD, Kuks JB, et al. Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia

- gravis in Dutch patients. *J Neuroimmunol* 2003;144:143-7.
63. Raknes G, Skeie GO, Gilhus NE, et al. FcγRIIA and FcγRIIIB polymorphisms in myasthenia gravis. *J Neuroimmunol* 1998;81:173-6.
 64. Zhang J, Chen Y, Jia G, et al. FOXP3 -3279 and IVS9+459 polymorphisms are associated with genetic susceptibility to myasthenia gravis. *Neurosci Lett* 2013;534:274-8.
 65. Chuang WY, Strobel P, Belharazem D, et al. The PTPN22 gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. *Genes Immun* 2009;10:667-72.
 66. Greve B, Hoffmann P, Illes Z, et al. The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. *Hum Immunol* 2009;70:540-2.
 67. Lefvert AK, Zhao Y, Ramanujam R, et al. PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. *J Neuroimmunol* 2008;197:110-3.
 68. Kaya GA, Coskun AN, Yilmaz V, et al. The Association of PTPN22 R620W Polymorphism Is Stronger with Late-Onset AChR-Myasthenia Gravis in Turkey. *Plos One* 2014;9.
 69. Vandiedonck C, Capdevielle C, Giraud M, et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. *Ann Neurol* 2006;59:404-7.
 70. Provenzano C, Ricciardi R, Scuderi F, et al. PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data. *Neuromuscul Disord* 2012;22:131-8.
 71. Xiong X, Xiang M, Cheng X, et al. PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-Analysis. *Med Sci Monit* 2015;21:2567-71.
 72. Zheng J, Ibrahim S, Petersen F, et al. Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue. *Genes Immun* 2012;13:641-52.
 73. Gregersen PK, Kosoy R, Lee AT, et al. Risk for myasthenia gravis maps to a (151) Pro-->Ala change in TNIP1 and to human leukocyte antigen-B*08. *Ann Neurol* 2012;72:927-35.
 74. Yilmaz V, Tutuncu Y, Baris Hasbal N, et al. Polymorphisms of interferon-gamma, interleukin-10, and interleukin-12 genes in myasthenia gravis. *Hum Immunol* 2007;68:544-9.
 75. Yang LL, Wang JJ, Sun XS, et al. Identifying a Polymorphic 'Switch' That Influences miRNAs' Regulation of a Myasthenia Gravis Risk Pathway. *Plos One* 2014;9.
 76. Pal Z, Varga Z, Semsei A, et al. Interleukin-4 receptor alpha polymorphisms in autoimmune myasthenia gravis in a Caucasian population. *Hum Immunol* 2012;73:193-5.
 77. Sciacca FL, Ferri C, Veglia F, et al. IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset. *J Neuroimmunol* 2002;122:94-9.
 78. Huang D, Pirskanen R, Hjelmstrom P, et al. Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. *J Neuroimmunol* 1998;81:76-81.
 79. Huang D, Zheng C, Giscombe R, et al. Polymorphisms at -174 and in the 3' flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis. *Journal of neuroimmunology* 1999;101:197-200.
 80. Huang DR, Zhou YH, Xia SQ, et al. Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: implications of diverse effects of IL-10 in the pathogenesis of the disease. *J Neuroimmunol* 1999;94:82-7.
 81. Zagoriti Z, Georgitsi M, Giannakopoulou O, et al. Genetics of myasthenia gravis: a case-control association study in the Hellenic population. *Clin Dev Immunol* 2012;2012:484919.
 82. Alseth EH, Nakkestad HL, Aarseth J, et al. Interleukin-10 promoter polymorphisms in myasthenia gravis. *J Neuroimmunol* 2009;210:63-6.
 83. Yue YX, Hong Y, Xie Y, et al. Association study between IL-17A and IL-17F gene polymorphism and myasthenia gravis in Chinese patients. *Neurol Sci* 2016;37:123-30.
 84. Pal Z, Antal P, Millinghoffer A, et al. A novel galectin-1 and interleukin 2 receptor beta haplotype is associated with autoimmune myasthenia gravis. *J Neuroimmunol* 2010;229:107-11.
 85. Pal Z, Antal P, Srivastava SK, et al. Non-synonymous single nucleotide polymorphisms in genes for immunoregulatory galectins: association of galectin-8 (F19Y) occurrence with autoimmune diseases in a Caucasian population. *Biochim Biophys Acta* 2012;1820:1512-8.

86. Kellermayer B, Polgar N, Pal J, et al. Association of myasthenia gravis with polymorphisms in the gene of histamine N-methyltransferase. *Hum Immunol* 2013;74:1701-4.
87. Fekih-Mrissa N, Klai S, Zaouali J, et al. Association of HLA-DR/DQ polymorphism with myasthenia gravis in Tunisian patients. *Clin Neurol Neurosurg* 2013;115:32-6.
88. Zhu WH, Lu JH, Lin J, et al. HLA-DQA1*03:02/DQB1*03:03:02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese. *J Neuroimmunol* 2012;247:81-5.
89. Yang H, Hao J, Peng X, et al. The association of HLA-DQA1*0401 and DQB1*0604 with thymomatous myasthenia gravis in northern Chinese patients. *J Neurol Sci* 2012;312:57-61.
90. Testi M, Terracciano C, Guagnano A, et al. Association of HLA-DQB1 *05:02 and DRB1 *16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis. *Autoimmune Dis* 2012;2012:541760.
91. Hajeer AH, Sawidan FA, Bohlega S, et al. HLA class I and class II polymorphisms in Saudi patients with myasthenia gravis. *Int J Immunogenet* 2009;36:169-72.
92. Yousefipour GA, Salami Z, Farjadian S. Association of HLA-DQA1*0101/2 and DQB1*0502 with myasthenia gravis in southern Iranian patients. *Iran J Immunol* 2009;6:99-102.
93. Saruhan-Direskeneli G, Kilic A, Parman Y, et al. HLA-DQ polymorphism in Turkish patients with myasthenia gravis. *Hum Immunol* 2006;67:352-8.
94. Hjelmstrom P, Giscombe R, Lefvert AK, et al. Polymorphic amino acid domains of the HLA-DQ molecule are associated with disease heterogeneity in myasthenia gravis. *J Neuroimmunol* 1996;65:125-31.
95. Pal Z, Gal A, Remenyi V, et al. Oestrogen receptor alpha gene intronic polymorphisms and autoimmune myasthenia gravis in Caucasian women. *Neuromuscul Disord* 2009;19:822-4.
96. Sakthivel P, Ramanujam R, Wang XB, et al. Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. *J Neuroimmunol* 2008;193:149-55.
97. Na SJ, Lee JH, Kim SW, et al. Whole-genome analysis in Korean patients with autoimmune myasthenia gravis. *Yonsei Med J* 2014;55:660-8.
98. Kokunai Y, Goto K, Kubota T, et al. A sodium channel myotonia due to a novel SCN4A mutation accompanied by acquired autoimmune myasthenia gravis. *Neurosci Lett* 2012;519:67-72.
99. Nel M, Buys JM, Rautenbach R, et al. The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis. *J Hum Genet* 2015.
100. Zheng K, Xu GW, Lu X, et al. Expression and polymorphisms of T cell immunoglobulin domain and mucin domain protein-1 in thymoma with or without myasthenia gravis. *Oncology Letters* 2014;8:317-22.
101. Zheng K, Xu G, Lu X, et al. Expression and polymorphisms of T cell immunoglobulin domain and mucin domain protein-1 in thymoma with or without myasthenia gravis. *Oncol Lett* 2014;8:317-22.
102. Xu G, Zheng K, Lu X, et al. Association between polymorphisms in the promoter region of T cell immunoglobulin and mucin domain-3 and myasthenia gravis-associated thymoma. *Oncol Lett* 2015;9:1470-4.
103. Guan YZ, Cui LY, Li YF, et al. Tumor necrosis factor-alpha polymorphism and secretion in myasthenia gravis. *Chin Med Sci J* 2005;20:104-7.
104. Huang DR, Pirskanen R, Matell G, et al. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. *J Neuroimmunol* 1999;94:165-71.
105. Yang HW, Xie Y, Zhao Y, et al. TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis. *Medicine (Baltimore)* 2017;96:e6798.
106. Zelano G, Lino MM, Evoli A, et al. Tumour necrosis factor beta gene polymorphisms in myasthenia gravis. *Eur J Immunogenet* 1998;25:403-8.
107. Hjelmstrom P, Peacock CS, Giscombe R, et al. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis. *J Neuroimmunol* 1998;88:137-43.
108. Han J, Li H, Xie Y, et al. [Association between vitamin D receptor gene Tru9I polymorphism and myasthenia gravis]. *Zhonghua yi xue za zhi* 2012;92:2028-33.
109. Jiang L, Cheng Z, Qiu S, et al. Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. *Int Immunopharmacol* 2012;14:217-23.

110. Zhang J, Jia G, Liu Q, et al. Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis. *Immunology* 2015;144:56-67.
111. Lu J, Yan M, Wang Y, et al. Altered expression of miR-146a in myasthenia gravis. *Neurosci Lett* 2013;555:85-90.
112. Wang J, Zheng S, Xin N, et al. Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response. *J Neuroimmune Pharmacol* 2013;8:1287-302.
113. Wang YZ, Tian FF, Yan M, et al. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis. *Clinical and Experimental Immunology* 2014;176:207-21.
114. Nogales-Gadea G, Ramos-Fransi A, Suarez-Calvet X, et al. Analysis of serum miRNA profiles of myasthenia gravis patients. *PLoS One* 2014;9:e91927.
115. Cheng ZA, Qiu SB, Jiang L, et al. MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1. *Journal of Clinical Immunology* 2013;33:567-76.
116. Punga T, Le Panse R, Andersson M, et al. Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker. *Ann Clin Transl Neurol* 2014;1:49-58.
117. Wang YZ, Tian FF, Yan M, et al. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis. *Clin Exp Immunol* 2014;176:207-21.
118. Chunjie N, Huijuan N, Zhao Y, et al. Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients. *Eur Cytokine Netw* 2015;26:61-6.
119. Zhang Y, Guo M, Xin N, et al. Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis. *Clin Exp Med* 2016;16:413-21.
120. Punga T, Bartoccioni E, Lewandowska M, et al. Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. *J Neuroimmunol* 2016;292:21-6.
121. Punga AR, Andersson M, Alimohammadi M, et al. Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. *J Neurol Sci* 2015;356:90-6.